The baseline characteristics showed a higher proportion of patients with invasive ductal carcinoma (78.6% & 80.8%), ER positive (70.3% & 71.3%), and HER2 negative (70.0% & 68.9%) subtypes in both cohorts. The gene discussed is ERBB2; the disease is invasive ductal breast carcinoma.